Systemic Amyloidosis
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AttralusFL - Naples
1 program1
99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.Phase 1Peptide1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Attralus99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.
Clinical Trials (1)
Total enrollment: 35 patients across 1 trials
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Start: Jul 2023Est. completion: Dec 202535 patients
Phase 1Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.